Minerva Neurosciences (NERV) Metrics: History & Chart

Minerva Neurosciences, Inc.(NERV)

Biotechnology · Burlington, MA

$3.42+0.10 (+3.01%)

Delayed quote: Oct 6, 2026, 12:30 PM EDT

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

Burlington, MA

7 employees

www.minervaneurosciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Remy Luthringer

View full financials

Third-Party DCF Estimate (FMP)	$1.98
Price Gap vs Third-Party Estimate	-40.18%

7D Total Return	-2.35%
30D Total Return	-25.06%
YTD Total Return	-17.41%
1Y Total Return	+58.10%
3Y Total Return	-46.63%
5Y Total Return	-71.38%
10Y Total Return	-97.08%
15Y Total Return	N/A
20Y Total Return	N/A

2026	-17.41%
2025	+81.08%
2024	-63.90%
2023	+286.79%
2022	-75.20%
2021	-65.76%
2020

CAGR TTM	+57.75%
CAGR 3Y	-18.88%
CAGR 5Y	-22.14%
CAGR 10Y	-29.77%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	2.58
PE Ratio Avg TTM	4.03
PE Ratio Avg 3Y	4.03
Current VS TTM Avg	-36.03%
Current VS 3Y Avg	-36.03%
Current VS 5Y Avg	-63.22%

All Metrics

NERV Valuation Metrics

NERV Stock Price Metrics

NERV Dividend Metrics

NERV Growth Rate Metrics

NERV Discounted Cash Flow Metrics

NERV Returns By Period

NERV Yearly Returns

NERV Average Annual Returns By Period (CAGR)

NERV Revenue Metrics

NERV PE Ratio Metrics

NERV PS Ratio Metrics

NERV PB Ratio Metrics

NERV Price to Free Cash Flow Ratio Metrics

NERV Debt to Equity Ratio Metrics

NERV PEG Ratio Metrics

NERV FCF Yield

NERV Earnings Yield

NERV EBITDA Yield

NERV OCF Yield

NERV EV/EBIT Ratio Metrics

NERV EV/EBITDA Ratio Metrics

NERV EV/Assets Ratio Metrics

NERV EV/Sales Ratio Metrics

NERV Current Ratio Metrics

NERV Quick Ratio Metrics

NERV ROIC Metrics

NERV Return on Assets Metrics

NERV Return on Equity Metrics

NERV Net Profit Margin Metrics

NERV Gross Profit Margin Metrics

NERV Tax Rate Metrics

PS Ratio	1.91
PS Ratio Avg TTM	2.98
PS Ratio Avg 3Y	2.98
Current VS TTM Avg	-36.00%
Current VS 3Y Avg	-36.00%
Current VS 5Y Avg	-36.00%

PB Ratio	2.68
PB Ratio Avg TTM	2.13
PB Ratio Avg 3Y	3.12
Current VS TTM Avg	+26.09%
Current VS 3Y Avg	-14.22%
Current VS 5Y Avg	+0.05%

PFCF Ratio	77.06
PFCF Ratio Avg TTM	78.89
PFCF Ratio Avg 3Y	78.89
Current VS TTM Avg	-2.32%
Current VS 3Y Avg	-2.32%
Current VS 5Y Avg	-2.32%

Debt/Equity Ratio	0.00
Debt/Equity Ratio Avg TTM	(0.05)
Debt/Equity Ratio Avg 3Y	0.00
Current VS TTM Avg	+100.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	1.30%
FCF Yield Avg TTM	1.28%
FCF Yield Avg 3Y	1.28%
Current VS TTM Avg	+1.77%
Current VS 3Y Avg	+1.77%
Current VS 5Y Avg	+1.77%

Earnings Yield	38.74%
Earnings Yield Avg TTM	39.99%
Earnings Yield Avg 3Y	39.99%
Current VS TTM Avg	-3.12%
Current VS 3Y Avg	-3.12%
Current VS 5Y Avg	+43.99%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	0.23
Ev/Ebit Ratio Avg TTM	24.87
Ev/Ebit Ratio Avg 3Y	24.87
Current VS TTM Avg	-99.08%
Current VS 3Y Avg	-99.08%
Current VS 5Y Avg	-99.08%

Ev/Ebitda Ratio	0.22
Ev/Ebitda Ratio Avg TTM	22.86
Ev/Ebitda Ratio Avg 3Y	22.86
Current VS TTM Avg	-99.04%
Current VS 3Y Avg	-99.04%
Current VS 5Y Avg	-99.04%

Ev/Assets Ratio	2.50
Ev/Assets Ratio Avg TTM	1.70
Ev/Assets Ratio Avg 3Y	1.24
Current VS TTM Avg	+47.41%
Current VS 3Y Avg	+101.85%
Current VS 5Y Avg	+138.41%

Ev/Sales Ratio	0.04
Ev/Sales Ratio Avg TTM	2.12
Ev/Sales Ratio Avg 3Y	2.12
Current VS TTM Avg	-98.11%
Current VS 3Y Avg	-98.11%
Current VS 5Y Avg	-98.11%

Current Ratio	20.14
Current Ratio Avg TTM	17.02
Current Ratio Avg 3Y	12.21
Current VS TTM Avg	+18.36%
Current VS 3Y Avg	+65.00%
Current VS 5Y Avg	+24.53%

Quick Ratio	20.14
Quick Ratio Avg TTM	17.02
Quick Ratio Avg 3Y	12.21
Current VS TTM Avg	+18.36%
Current VS 3Y Avg	+65.00%
Current VS 5Y Avg	+24.53%

ROIC	(38.56%)
ROIC Avg 3Y	(47.17%)
ROIC Avg 5Y	(49.69%)
Current VS 3Y Avg	+18.26%
Current VS 5Y Avg	+22.39%
Current VS 10Y Avg	+5.07%

ROA	(414.72%)
ROA Avg TTM	(85.01%)
ROA Avg 3Y	(12.85%)
Current VS TTM Avg	-387.87%
Current VS 3Y Avg	-3127.62%
Current VS 5Y Avg	-3223.64%

ROE	N/A
ROE Avg TTM	(166.93%)
ROE Avg 3Y	(59.53%)
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A